|
rs4374383
|
|
|
0.030 |
GeneticVariation |
BEFREE |
<i>MERTK</i> rs4374383 A carriers had a lower risk of liver fibrosis progression than G carriers, supporting the hypothesis that this SNP seems to have a critical role in the pathogenesis of liver disease in HCV-infected patients.
|
30477195 |
2018 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
C282Y or H63D heterozygosity is an independent risk factor for liver fibrosis and cirrhosis in HCV infected individuals.
|
12586300 |
2003 |
|
rs58542926
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A common non-synonymous polymorphism in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys) was recently associated with increased hepatic triglyceride content, but whether this variant promotes clinically relevant hepatic fibrosis is unknown.
|
24978903 |
2014 |
|
rs58542926
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A common non-synonymous polymorphism, E167K, in transmembrane six superfamily member 2 (TM6SF2) gene has been recently associated with an increased hepatic triglyceride content, dyslipidemia and liver fibrosis in NAFLD patients.
|
25581573 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A genetic variant in adiponutrin (PNPLA3) gene, rs738409 C/G, is associated with steatosis, severity, and progression of liver fibrosis in CHC patients, and predicts treatment outcome in difficult-to-cure HCV-infected patients with advanced fibrosis.
|
26389885 |
2015 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A minimum of .66% C282Y homozygotes have liver fibrosis.
|
16797244 |
2006 |
|
rs267606959
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
A novel POLG gene mutation in 4 children with Alpers-like hepatocerebral syndromes.
|
20142534 |
2010 |
|
rs7080536
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A single nucleotide polymorphism (G534E, Marburg I, MI-SNP) in the gene encoding FSAP (HABP2) leads to lower enzymatic activity and is associated with enhanced liver fibrosis in humans.
|
22989567 |
2013 |
|
rs7080536
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A single nucleotide polymorphism (G534E) in HABP2 leads to lower enzymatic activity and is associated with enhanced liver fibrosis in humans.
|
27462075 |
2016 |
|
rs28934571
|
|
|
0.010 |
GeneticVariation |
BEFREE |
About 1/3 of carriers have moderate to severe liver fibrosis and 60% have detectable aflatoxin-related TP53 R249S mutation.
|
25886382 |
2015 |
|
rs13412852
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Affected children carrying the rs13412852 TT genotype had a trend for a lower prevalence of nonalcoholic steatohepatitis, and significantly less severe liver damage, as indicated by NAFLD activity score severity (P = 0.026) and a lower prevalence of liver fibrosis (P = 0.012).
|
22157924 |
2012 |
|
rs7041
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although the rs7041 and rs4588 GC polymorphisms are strong predictors of vitamin D levels, they do not play a direct role in liver fibrosis.
|
28809744 |
2018 |
|
rs4588
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although the rs7041 and rs4588 GC polymorphisms are strong predictors of vitamin D levels, they do not play a direct role in liver fibrosis.
|
28809744 |
2018 |
|
rs4986790
|
|
|
0.010 |
GeneticVariation |
BEFREE |
At stepwise logistic regression analysis, the carriage of TLR-4 rs4986790 A/A genotype was found to be and independent predictor of liver fibrosis (O.R.14.8, p = 0.019).
|
23093310 |
2013 |
|
rs12785878
|
|
|
0.010 |
GeneticVariation |
BEFREE |
By multivariate analysis, liver fibrosis stage 0-1 (OR = 5.00; 95% CI, 2.02-12.37; P < 0.001), and DHCR7 rs12785878 GT/TT allele (OR = 2.69; 95% CI, 1.03-7.05; P = 0.04) were independent pre-treatment predictors of SVR following PEG-IFN-based therapy in HCV genotype 1 patients.
|
28415985 |
2017 |
|
rs1799945
|
|
|
0.020 |
GeneticVariation |
BEFREE |
C282Y or H63D heterozygosity is an independent risk factor for liver fibrosis and cirrhosis in HCV infected individuals.
|
12586300 |
2003 |
|
rs8099917
|
|
|
0.070 |
GeneticVariation |
BEFREE |
During observation, 131 patients with chronic infection underwent a liver biopsy; age (OR 1.058; P = 0.01) G/T or G/G genotypes of rs8099917 polymorphism (OR 3.962; P = 0.001), and C/T or T/T genotypes of rs12979860 polymorphism (OR 3.494; P = 0.005) were associated with severe liver fibrosis, independent of liver iron concentration.
|
22180419 |
2012 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
During observation, 131 patients with chronic infection underwent a liver biopsy; age (OR 1.058; P = 0.01) G/T or G/G genotypes of rs8099917 polymorphism (OR 3.962; P = 0.001), and C/T or T/T genotypes of rs12979860 polymorphism (OR 3.494; P = 0.005) were associated with severe liver fibrosis, independent of liver iron concentration.
|
22180419 |
2012 |
|
rs3480
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
|
28472477 |
2017 |
|
rs3194051
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Finally, patients with rs3194051 AA genotype had higher odds of having severe liver fibrosis (F ≥ 3; APRI ≥1.5, and FIB4 ≥3.25) than patients with rs3194051 AG/GG genotype [aOR = 2.73 (p = 0.010); aOR = 2.52 (p = 0.029); and aOR = 4.01 (p = 0.027); respectively].
|
26123260 |
2015 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we briefly highlight future research that may elucidate the specific mechanisms of the PNPLA3 I148M variant in fibrogenesis, which, in turn, provides a theoretical foundation and valuable experimental data for the clinical management of nonalcoholic fatty liver fibrosis.
|
25624712 |
2015 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For C282Y heterozygous patients, the odds ratios for marked inflammatory activity (A2-4) and advanced liver fibrosis or cirrhosis (F2-4) are 4.9 and 4.6, respectively, compared with patients carrying homozygous wild-type alleles.
|
15287851 |
2004 |
|
rs1801282
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Furthermore, rs1801282 CG/GG was associated with low values of HOMA-IR (aAMR = 0.69 (95% CI = 0.49; 0.98); p = 0.038) among patients with significant liver fibrosis (F ≥ 2).
|
25159899 |
2014 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n=1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis.
|
24978903 |
2014 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic loci associated with iron metabolism (TF, TMPRSS6, PCSK7, TFR2 and Chr2p14) in recent GWAS and liver fibrosis (PNPLA3) in recent meta-analysis were analyzed for association with either liver cirrhosis or advanced fibrosis in 148 German HFE C282Y homozygotes.
|
24556216 |
2014 |